The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
Status:
Completed
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as
measured by subject diary in early stage COPD subjects who are experimentally infected with
rhinovirus.
Subjects will receive 1 dose of PUL-042 followed by inoculation with HRV A16 virus 24 hours
later. An additional dose of PUL-042 will be administered 48 hours post-inoculation. Subjects
will be followed for 6 weeks post-inoculation
Phase:
Phase 2
Details
Lead Sponsor:
Pulmotect, Inc.
Collaborators:
Data Magik Ltd Imperial College Healthcare NHS Trust MWB Consulting Ltd VirTus Respiratory Research Ltd
Treatments:
Pam2CSK4 acetate and ODN M362 combination Pharmaceutical Solutions